CAS NO: | 250694-07-6 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Teglicar is a selective and reversible orally active liver isoform ofcarnitine palmitoyl-transferase 1 (L-CPT1)inhibitor with anIC50value of 0.68 μM and aKivalue of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD)[1][2]. | ||||||||||||||||||||||||||||||||
IC50& Target | IC50: 0.68 μM (L-CPT1); Ki: 0.36 μM (L-CPT1)[1] | ||||||||||||||||||||||||||||||||
体外研究 (In Vitro) | Teglicar has L-CPT1 inhibitory activity with anIC50value of 0.68 μM and aKivalue of 0.36 μM[1]. | ||||||||||||||||||||||||||||||||
体内研究 (In Vivo) | Teglicar (oral, 80 mg/kg, once a day, for 30 days or infusion, 5.3 mg/kg/h, for 3 h) reduces the endogenous glucose production (262%) without affecting peripheral glucose utilization in SD rats[1].
| ||||||||||||||||||||||||||||||||
分子量 | 399.61 | ||||||||||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||||||||||
Formula | C22H45N3O3 | ||||||||||||||||||||||||||||||||
CAS 号 | 250694-07-6 | ||||||||||||||||||||||||||||||||
中文名称 | 替格列卡 | ||||||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||||||
储存方式 |
| ||||||||||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : 19 mg/mL(47.55 mM;Need ultrasonic) H2O : 10 mg/mL(25.02 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|